公开(公告)号：US20210308242A1

公开(公告)日：2021-10-07

申请号：US17301704

申请日：2021-04-12

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： Gerard ZURAWSKI ,  Jacques F. Banchereau ,  Anne-Laure FLAMAR ,  Peter KLUCAR ,  Keiko AKAGAWA ,  Sandra ZURAWSKI ,  SangKon OH

IPC: A61K39/00 ,  C07K16/28 ,  C07K14/435

Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.

公开(公告)号：US20210221904A1

公开(公告)日：2021-07-22

申请号：US17301118

申请日：2021-03-25

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： Gerard ZURAWSKI ,  Jacques F. Banchereau ,  Anne-Laure FLAMAR ,  Yves Levy ,  Monica Montes

IPC: C07K16/28 ,  C07K14/005 ,  A61K39/385 ,  G01N33/68 ,  C07K16/00

Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.

公开(公告)号：US20200316191A1

公开(公告)日：2020-10-08

申请号：US16946390

申请日：2020-06-19

Applicant: INSERM (Institut National de la Sante et de la Recherche Medicate) ,  Baylor Research Institute ,  Universite Paris Est Creteil Val De Marne ,  Assistance Publique Hopitaux de Paris

Inventor： Yves LEVY ,  Gerard ZURAWSKI ,  Sandra ZURAWSKI ,  Anne-Laure FLAMAR

IPC: A61K39/21 ,  A61P31/18 ,  C07K14/005 ,  C12N7/00 ,  C07K16/28 ,  C07K16/10 ,  A61K39/12

Abstract: Methods and compositions are provided that can be used to vaccinate against and treat HIV. Specifically contemplated are vaccine compositions and methods of using these compositions treat HIV in patients. Aspects of the disclosure relate to an anti-CD40 antibody-HIV antigen fusion protein comprising (i) an anti-CD40 heavy chain (HCD40)-HIV antigen (Ag) fusion protein comprising the formula: HCD40-Ag, wherein Ag is a polypeptide with at least 80% sequence identity to SEQ ID NO:1; and (ii) an anti-CD40 light chain (LCD40).

公开(公告)号：US20200101152A1

公开(公告)日：2020-04-02

申请号：US16708787

申请日：2019-12-10

Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale) ,  Baylor Research Institute ,  Universite Paris Est Creteil Val De Marne ,  Assistance Publique Hopitaux de Paris

Inventor： Yves LEVY ,  Gerard ZURAWSKI ,  Sandra ZURAWSKI ,  Anne-Laure FLAMAR

IPC: A61K39/21 ,  A61P31/18 ,  C07K14/005 ,  C12N7/00 ,  C07K16/28 ,  C07K16/10 ,  A61K39/12

Abstract: Methods and compositions are provided that can be used to vaccinate against and treat HIV. Specifically contemplated are vaccine compositions and methods of using these compositions treat HIV in patients. Aspects of the disclosure relate to an anti-CD40 antibody-HIV antigen fusion protein comprising (i) an anti-CD40 heavy chain (HCD40)-HIV antigen (Ag) fusion protein comprising the formula: HCD40-Ag, wherein Ag is a polypeptide with at least 80% sequence identity to SEQ ID NO:1; and (ii) an anti-CD40 light chain (LCD40).